Immunis.AI selected by Amazon Web Services to showcase its cloud-based genomics pipeline for machine learning
ROYAL OAK, Michigan – (COMMERCIAL THREAD) – Immunis.AI, Inc., an immunogenomics platform company that develops non-invasive blood tests to optimize patient care, today announced that Amazon Web Services (AWS) will showcase the genomics pipeline company’s cloud-based machine learning. In collaboration with Mission Cloud Services, the platform will be highlighted during a virtual event, Behind the innovation, hosted by AWS, today.
Immunis.AI hired Mission, a partner with deep life science expertise, to design an AWS architecture to leverage Amazon S3 as well as a backend data pipeline using Amazon EC2 and Amazon EBS infrastructure. . The challenge Immunis.AI faced was data ingestion and real-time analysis of its large immunotranscriptomic datasets and parallel processing of thousands of samples through its machine learning pipelines. Thanks to the collaboration with Mission and AWS, data ingestion by Immunis.AI, which took two weeks to complete manually, can be completed in a matter of hours.
The virtual event, which will be held on Tuesday, October 5e9 a.m. to 10:30 a.m. Pacific Time (12 p.m. to 1:30 p.m. Eastern Time). For more information or to register for the virtual event, click here.
“Machine learning presents its own unique set of challenges, and managing large data sets is a major problem in genomics. Working with Mission and AWS to design an architecture to streamline our ingestion and data analysis has enabled us to significantly accelerate the development of our immunogenomic assays to improve the diagnosis and treatment of cancer patients, ”said Geoffrey Erickson , Founder and Senior Vice President of Corporate Development. to Immunis.AI, who will be presenting at the event. “We are thrilled to have been chosen by AWS to showcase our architecture and powerful partnership and the life-changing results it enables. ”
“While still evolving, Mission has provided Immunis.AI with a tested and proven model for a viable research-oriented genomic platform, all backed by AWS and ready to scale quickly and economically, ”said Jonathan LaCour, Chief Technology Officer and Senior Vice President. , Delivery service. “We are excited to support Immunis.AI’s important mission of developing tests that can improve the lives of cancer patients and proud of its Mission-built AWS infrastructure that helps them. ”
Immunis.AI continues to build on its successful model through multiple clinical studies as it develops and plans to market its products. The mission will also continue to assist Immunis.AI in data modernization, including data lake and analytics initiatives on AWS.
About Immunis.AI, Inc.
IMMUNIS.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique disease biology information and individualized assessment. The Intelligentia platform combines the power of the immune system, RNAseq technology and machine learning (ML) for the development of disease-specific signatures. This proprietary method uses the immune system monitoring apparatus to overcome the limitations of circulating tumor cells (CTC) and cell-free DNA (cfDNA). The platform improves disease detection at an early stage, to the point of immune breakout, when there is the greatest opportunity for a cure. For more information, please visit our website: https://immunis.ai/